March 31 2015 Issue

1) When a serum test overrides the clinical assessment and 2) Topic of the month: Stroke in systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Josep Dalmau about his paper on when a serum test overrides the clinical assessment. Dr. James Addington is reading our e-Pearl of the week about lissencephaly. In the next part of the podcast Dr. Michelle Johansen interviews Dr. Mitch Elkind about the topic of stroke in the setting of systemic infection. The participants had nothing to disclose except Drs. Dalmau, Addington, Johansen and Elkind.Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Johansen serves as a scientific advisory member of Stroke and as a contributor to Blogging Stroke.Dr. Elkind serves as Section editor for the Neurology® Resident and Fellow Section; serves on the scientific advisory board for Biogen IDEC, Boehringer Ingelheim, BMS-Pfizer Partnership, Janssen Pharmaceutical; is a consultant for Daiichi Sankyo, BMS-Pfizer Partnership and Biotelemetry; participated in legal proceedings for Organon/Merck Serono, NuvaRing and stroke litigation; receives research support from American Heart Association National Board of Directors, American Heart Association Founders Affiliate Board of Directors, American Heart Association NY City Board of Directors and the NIH.